by Plus Therapeutics | Nov 24, 2025 | LM
Plus Therapeutics announced that it has successfully completed a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss the Company’s clinical development plans for REYOBIQ™, its targeted radiotherapeutic for leptomeningeal metastases (LM). The...
by Plus Therapeutics | Nov 10, 2025 | LM
Each November, Lung Cancer Awareness Month serves as a national reminder of the impact lung cancer has on patients, families, and communities. It is also a time to highlight the growing need for better diagnostic and treatment options—especially for patients facing...
by Plus Therapeutics | Nov 6, 2025 | LM
Plus Therapeutics is pleased to announce its participation at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting and the Melanoma Research Foundation (MRF) Brain Metastases Summit 4.0, taking place on November 9, 2025, in Alexandria, VA. This annual...
by Plus Therapeutics | Oct 14, 2025 | LM
Last week, CNSide® Medical Director Jonathan Stein, PhD, HCLD(ABB) presented at BioHouston’s October Life Science event — joining Houston’s growing network of researchers, entrepreneurs, and clinicians driving the future of biotech innovation. The discussion centered...
by Plus Therapeutics | Oct 13, 2025 | LM
Did you know that as many as 5% to 20% of people with advanced breast cancer may eventually develop leptomeningeal metastases (LM) — also known as leptomeningeal disease (LMD)? LM occurs when cancer cells spread to the membranes (meninges) that surround the brain and...
by Plus Therapeutics | Oct 13, 2025 | LM
Today marks Metastatic Breast Cancer Awareness Day — a time to honor those living with stage IV breast cancer, remember those we’ve lost, and reaffirm our shared commitment to ending the disease. While significant progress has been made in early-stage breast cancer...
Recent Comments